Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Yuan Fang, Guochao Liao, Bin Yu
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 7, pp. 1253-1278
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1742
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 194
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
Michael J. Bond, Craig M. Crews
RSC Chemical Biology (2021) Vol. 2, Iss. 3, pp. 725-742
Open Access | Times Cited: 159
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
Haohao Zhu, Hui Gao, Yingying Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 129
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 110
E3 ligase ligand chemistries: from building blocks to protein degraders
Izidor Sosič, Aleša Bricelj, Christian Steinebach
Chemical Society Reviews (2022) Vol. 51, Iss. 9, pp. 3487-3534
Closed Access | Times Cited: 88
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
The roles and regulation of MDM2 and MDMX: it is not just about p53
Alyssa M. Klein, Rafaela Muniz de Queiroz, Divya Venkatesh, et al.
Genes & Development (2021) Vol. 35, Iss. 9-10, pp. 575-601
Open Access | Times Cited: 95
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
Tingting Jiang, Guan Wang, Yao Liu, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 2, pp. 355-372
Open Access | Times Cited: 92
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Shuai Wang, Fen‐Er Chen
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114334-114334
Closed Access | Times Cited: 63
Akt: a key transducer in cancer
Pei‐Jane Tsai, Yi‐Hsin Lai, Rajesh Manne, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 61
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 54
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Xin Han, Wenyi Wei, Yi Sun
Acta Materia Medica (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 45
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Modern approaches to glioblastoma therapy
Natalya S. Kuznetsova, S. V. Gurova, А. С. Гончарова, et al.
South Russian Journal of Cancer (2023) Vol. 4, Iss. 1, pp. 52-64
Open Access | Times Cited: 24
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Youyi Huang, Xiaofang Che, Peter Wang, et al.
Seminars in Cancer Biology (2024) Vol. 101, pp. 44-57
Closed Access | Times Cited: 10
MDM2: current research status and prospects of tumor treatment
Yumei Yao, Qian Zhang, Zhi Li, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Effects of Mdm2 Inhibitors on Cellular Viability of Breast Cancer Cell Lines HP100, MCF7
Hany Akeel Al-Hussaniy, Mohammed J. AL-Zobaidy
Bratislavské lekárske listy/Bratislava medical journal (2024) Vol. 125, Iss. 10, pp. 627-634
Open Access | Times Cited: 8
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
Shipeng He, Junhui Ma, Yuxin Fang, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 6, pp. 1617-1628
Open Access | Times Cited: 61
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Ruqaia Abbas, Sarit Larisch
Cells (2021) Vol. 10, Iss. 12, pp. 3465-3465
Open Access | Times Cited: 52
Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
Hui Liu, Weimin Qiu, Tianyu Sun, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1781-1804
Open Access | Times Cited: 47
Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation
Saiyan Bian, Wenkai Ni, Mengqi Zhu, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 3, pp. 1022-1038
Open Access | Times Cited: 35
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Si Chen, Xiang Li, Yinghua Li, et al.
Theranostics (2022) Vol. 12, Iss. 15, pp. 6665-6681
Open Access | Times Cited: 29
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Jianyu Yan, Tengfei Li, Zhenyuan Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8798-8827
Closed Access | Times Cited: 28
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents
Silvia Salerno, Elisabetta Barresi, Emma Baglini, et al.
Molecules (2023) Vol. 28, Iss. 6, pp. 2587-2587
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top